DE4317078A1 - Method of maintaining the optimum oxygen content of the eye required for the vision of the healthy human being, especially of contact lens wearers - Google Patents

Method of maintaining the optimum oxygen content of the eye required for the vision of the healthy human being, especially of contact lens wearers

Info

Publication number
DE4317078A1
DE4317078A1 DE19934317078 DE4317078A DE4317078A1 DE 4317078 A1 DE4317078 A1 DE 4317078A1 DE 19934317078 DE19934317078 DE 19934317078 DE 4317078 A DE4317078 A DE 4317078A DE 4317078 A1 DE4317078 A1 DE 4317078A1
Authority
DE
Germany
Prior art keywords
oxygen
vision
contact lens
maintaining
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19934317078
Other languages
German (de)
Inventor
Hans Bruno Klomann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE19934317078 priority Critical patent/DE4317078A1/en
Publication of DE4317078A1 publication Critical patent/DE4317078A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H33/00—Bathing devices for special therapeutic or hygienic purposes
    • A61H33/14—Devices for gas baths with ozone, hydrogen, or the like
    • A61H2033/143—Devices for gas baths with ozone, hydrogen, or the like with oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H35/00—Baths for specific parts of the body
    • A61H35/02—Baths for specific parts of the body for the eyes

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The essential feature of my invention is the combination of adjustment of the correct moisture content of the eye surface in each particular case and simultaneous supply of the oxygen amount required for maintaining a "clear" vision. It is known that "artificial lacrimal fluids" are prescribed for moistening of excessively dry conjunctivae, that is to say, especially for contact lens wearers. These medicaments were, however, not designed by the pharmaceutical industry for oxygen therapy of the eyes. These products do not contain any oxygen or at most unintentional traces. However, in the above-mentioned group of patients, in particular, supply of oxygen to the eye is of utmost importance. In order to achieve maximum oxygen enrichment (e.g. 50 mg O2/l moistening fluid) of the various "artificial lacrimal fluids" which are usually supplied by the pharmaceutical industry in dropper bottles, I propose use of a mini-O2-compressed gas apparatus (travel apparatus) which can be used by anyone at any time. However, construction of this apparatus does not form part of my invention.

Description

Die Erfindung betrifft die Einstellung und die Aufrechterhaltung des, für ein ungestörtes, klares und scharfes Sehen, unbedingt notwendigen, normalen Sauerstoffgehaltes an und in den eigenen Augen, z. B. bei Conjunktivitis sicca (= zu trockener Bindehaut) und speziell beim Tragen von Kontaktlinsen.The invention relates to adjustment and maintenance for an undisturbed, clear and sharp vision, absolutely necessary, normal oxygen content on and in your own Eyes, e.g. B. in conjunctivitis sicca (= too dry conjunctiva) and especially when wearing contact lenses.

Der Sauerstoffgehalt in der Feuchtigkeit an der Augenoberfläche dürfte beim gesunden Menschen, in frischer Luft, bei etwa 10 mg O₂/Liter liegen.The oxygen content in the moisture on the surface of the eye should be around 10 mg in healthy people, in fresh air O₂ / liter.

Die Gewährleistung völlig unbeeinträchtigten Sehens durch vor­ liegende Verbesserung ist im Straßenverkehr von größter Wichtig­ keit.Ensuring completely unimpaired vision through before Horizontal improvement is of the utmost importance in road traffic speed.

Die Therapie mit gasförmigem Sauerstoff ist in der ärztlichen Augenheilkunde nicht unbekannt. Sie ist leider stationsgebunden und hält nur kurz vor.Therapy with gaseous oxygen is medical Ophthalmology is not unknown. Unfortunately, it is station-bound and only lasts a short time.

Das Problem des eintretenden Sauerstoffmangels ist den Kontakt­ linsenherstellern seit langem bekannt, weshalb sie mit porösen Linsen Abhilfe zu schaffen versuchten. M.E. nicht befriedigend. Es werden aber so ziemlich allen Kontaktlinsenträgern, und auch bei zu trockener Bindehaut ärztlicherseits sogenannte "künst­ liche Tränen" verschrieben, die der Patient zur Feuchthaltung der Binde- und Hornhaut und zur besseren Gleitung, zur Herab­ setzung der Reibung der Kontaktlinsen, nach Bedarfsfall bis zu stündlich, in Selbstbehandlung, aus überwiegend 10 ml Kunst­ stoff-Tropffläschchen in seine Augen eintropfen muß.The problem with the lack of oxygen is contact lens manufacturers have long been known, which is why they use porous Lentils tried to remedy the situation. M.E. not satisfying. But it will pretty much all contact lens wearers, and also if the conjunctiva is too dry, the doctor calls it "artificial liche tears "which the patient prescribed to keep moist the conjunctiva and cornea and for better gliding, for descending setting of the friction of the contact lenses, if necessary up to too hourly, in self-treatment, mostly from 10 ml art drip into his eyes.

Ursprünglich "Ringer-Lösung", sind heute mehrere, wesentlich bessere Produkte auf dem Markt, steril abgepackt und praktisch ohne nennenswerten Sauerstoffgehalt.Originally "Ringer's solution", several are now essential better products on the market, sterile packed and practical without significant oxygen content.

Hier knüpft meine Erfindung an: Die sowieso erforderliche dau­ ernde Feuchthaltung der Augen mittels der erwähnten pharma­ zeutischen Benetzungsmittel kombiniere ich mit einer konti­ nuierlichen Sauerstoff-Therapie, anwendbar zu Hause, auf der Reise oder wo auch immer.This is where my invention comes in: the duration required anyway  the eyes are kept moist with the aforementioned pharma I combine the wetting agent with a continuous one Nuclear oxygen therapy, applicable at home, on the Trip or wherever.

Vor dem jeweiligen Einträufeln der Augentropfen müssen dazu die üblichen Tropffläschchen samt Inhalt unter schwachem Über­ druck, von beispielsweise 4 bar, mit reinem Sauerstoff begast werden. Im Benetzungsmittel werden beachtliche Sauerstoff­ sättigungen von etwa 50 mg O₂/Liter erreicht, als augener­ frischende, anhaltende Sauerstoffdusche bei der durchgeführten Selbstbehandlung.Before instilling the eye drops, you need to do this the usual dropper bottles and their contents with a slight overflow pressure, for example 4 bar, gassed with pure oxygen become. There is considerable oxygen in the wetting agent saturations of about 50 mg O₂ / liter reached when eye fresh, persistent oxygen shower at the performed Self-treatment.

Die erforderliche Druckbegasungsapparatur mit Minisauerstoff- Flasche, eventuellem Druckmanometer und Tropffläschchenhalte­ rung ist nicht Gegenstand der vorliegenden Erfindung. Notfalls läßt sie sich auch unschwer im Eigenbau zusammenstellen, wie die beigefügte Abbildung zeigt. Es ist nur ein Wink an die Arzneimittel- und an die einschlägige Geräte-Industrie beab­ sichtigt.The required pressurized gas equipment with mini oxygen Bottle, possibly pressure manometer and dropper bottle holder tion is not the subject of the present invention. If necessary it can also be put together easily, like the attached figure shows. It's just a hint to them Pharmaceutical and to the relevant equipment industry inspects.

Claims (2)

1. Verfahren zur Naß-Therapie bei unter Sauerstoffmangel leidenden Augenpatienten, allgemein bei zu trockener Bindehaut, speziell bedingt durch das Tragen von Kon­ taktlinsen.1. Procedure for wet therapy in the case of lack of oxygen suffering eye patients, generally if they are too dry Conjunctiva, especially due to wearing cones tactical lenses. 2. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß jedes augenverträgliche Benetzungsmittel unter Druck mit Sauerstoff wesentlich angereichert wird, beispiels­ weise auf 50 mg O₂/l. Der ebenfalls nur beispielsweise Sättigungsdruck von 4 bar ist abhängig vom Material der Tropffläschchen, üblicherweise PE.2. The method according to claim 1, characterized in that every wetting agent that is compatible with the eyes is under pressure is significantly enriched with oxygen, for example point to 50 mg O₂ / l. The also only for example saturation pressure of 4 bar depends on the material of the dropper bottle, usually PE.
DE19934317078 1993-05-21 1993-05-21 Method of maintaining the optimum oxygen content of the eye required for the vision of the healthy human being, especially of contact lens wearers Withdrawn DE4317078A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19934317078 DE4317078A1 (en) 1993-05-21 1993-05-21 Method of maintaining the optimum oxygen content of the eye required for the vision of the healthy human being, especially of contact lens wearers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19934317078 DE4317078A1 (en) 1993-05-21 1993-05-21 Method of maintaining the optimum oxygen content of the eye required for the vision of the healthy human being, especially of contact lens wearers

Publications (1)

Publication Number Publication Date
DE4317078A1 true DE4317078A1 (en) 1994-11-24

Family

ID=6488682

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19934317078 Withdrawn DE4317078A1 (en) 1993-05-21 1993-05-21 Method of maintaining the optimum oxygen content of the eye required for the vision of the healthy human being, especially of contact lens wearers

Country Status (1)

Country Link
DE (1) DE4317078A1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7654728B2 (en) * 1997-10-24 2010-02-02 Revalesio Corporation System and method for therapeutic application of dissolved oxygen
US7770814B2 (en) 1997-10-24 2010-08-10 Revalesio Corporation System and method for irrigating with aerated water
US7806584B2 (en) 1997-10-24 2010-10-05 Revalesio Corporation Diffuser/emulsifier
US7832920B2 (en) 2006-10-25 2010-11-16 Revalesio Corporation Mixing device for creating an output mixture by mixing a first material and a second material
US8349191B2 (en) 1997-10-24 2013-01-08 Revalesio Corporation Diffuser/emulsifier for aquaculture applications
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
US8591957B2 (en) 2006-10-25 2013-11-26 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US8609148B2 (en) 2006-10-25 2013-12-17 Revalesio Corporation Methods of therapeutic treatment of eyes
US8617616B2 (en) 2006-10-25 2013-12-31 Revalesio Corporation Methods of wound care and treatment
US8784898B2 (en) 2006-10-25 2014-07-22 Revalesio Corporation Methods of wound care and treatment
US8784897B2 (en) 2006-10-25 2014-07-22 Revalesio Corporation Methods of therapeutic treatment of eyes
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
US8980325B2 (en) 2008-05-01 2015-03-17 Revalesio Corporation Compositions and methods for treating digestive disorders
US9198929B2 (en) 2010-05-07 2015-12-01 Revalesio Corporation Compositions and methods for enhancing physiological performance and recovery time
US9492404B2 (en) 2010-08-12 2016-11-15 Revalesio Corporation Compositions and methods for treatment of taupathy
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349191B2 (en) 1997-10-24 2013-01-08 Revalesio Corporation Diffuser/emulsifier for aquaculture applications
US7770814B2 (en) 1997-10-24 2010-08-10 Revalesio Corporation System and method for irrigating with aerated water
US7806584B2 (en) 1997-10-24 2010-10-05 Revalesio Corporation Diffuser/emulsifier
US9034195B2 (en) 1997-10-24 2015-05-19 Revalesio Corporation Diffuser/emulsifier for aquaculture applications
US7654728B2 (en) * 1997-10-24 2010-02-02 Revalesio Corporation System and method for therapeutic application of dissolved oxygen
US8445546B2 (en) 2006-10-25 2013-05-21 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
US9402803B2 (en) 2006-10-25 2016-08-02 Revalesio Corporation Methods of wound care and treatment
US7919534B2 (en) 2006-10-25 2011-04-05 Revalesio Corporation Mixing device
US8449172B2 (en) 2006-10-25 2013-05-28 Revalesio Corporation Mixing device for creating an output mixture by mixing a first material and a second material
US8470893B2 (en) 2006-10-25 2013-06-25 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
US8591957B2 (en) 2006-10-25 2013-11-26 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US8597689B2 (en) 2006-10-25 2013-12-03 Revalesio Corporation Methods of wound care and treatment
US8609148B2 (en) 2006-10-25 2013-12-17 Revalesio Corporation Methods of therapeutic treatment of eyes
US8617616B2 (en) 2006-10-25 2013-12-31 Revalesio Corporation Methods of wound care and treatment
US8784898B2 (en) 2006-10-25 2014-07-22 Revalesio Corporation Methods of wound care and treatment
US8784897B2 (en) 2006-10-25 2014-07-22 Revalesio Corporation Methods of therapeutic treatment of eyes
US9512398B2 (en) 2006-10-25 2016-12-06 Revalesio Corporation Ionic aqueous solutions comprising charge-stabilized oxygen-containing nanobubbles
US8962700B2 (en) 2006-10-25 2015-02-24 Revalesio Corporation Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures
US9511333B2 (en) 2006-10-25 2016-12-06 Revalesio Corporation Ionic aqueous solutions comprising charge-stabilized oxygen-containing nanobubbles
US9004743B2 (en) 2006-10-25 2015-04-14 Revalesio Corporation Mixing device for creating an output mixture by mixing a first material and a second material
US8410182B2 (en) 2006-10-25 2013-04-02 Revalesio Corporation Mixing device
US7832920B2 (en) 2006-10-25 2010-11-16 Revalesio Corporation Mixing device for creating an output mixture by mixing a first material and a second material
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US8980325B2 (en) 2008-05-01 2015-03-17 Revalesio Corporation Compositions and methods for treating digestive disorders
US9272000B2 (en) 2009-04-27 2016-03-01 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
US9011922B2 (en) 2009-04-27 2015-04-21 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
US9198929B2 (en) 2010-05-07 2015-12-01 Revalesio Corporation Compositions and methods for enhancing physiological performance and recovery time
US9492404B2 (en) 2010-08-12 2016-11-15 Revalesio Corporation Compositions and methods for treatment of taupathy

Similar Documents

Publication Publication Date Title
DE4317078A1 (en) Method of maintaining the optimum oxygen content of the eye required for the vision of the healthy human being, especially of contact lens wearers
Heyboer III et al. Hyperbaric oxygen therapy: side effects defined and quantified
WEI et al. Determinants of response of pial arteries to norepinephrine and sympathetic nerve stimulation
Garssen et al. Agoraphobia and the hyperventilation syndrome
Holden et al. The etiology of transient endothelial changes in the human cornea.
Fischer et al. Human precorneal tear film pH measured by microelectrodes
Clarke et al. On the localization of Troxler's effect in the visual pathway
Quigley Reappraisal of the mechanisms of glaucomatous optic nerve damage
Weissman et al. Diffusion of oxygen in human corneas in vivo.
Carlisle et al. Hyperbaric oxygen and persistence of vision in retinal ischemia
Ali et al. Progression of retinal nerve fiber myelination in childhood
Papst et al. Changes in pO 2 induce retinal autoregulation in vitro
Nuotto Psychomotor, physiological and cognitive effects of scopolamine and ephedrine in healthy man
Wald et al. Respiratory effects upon the visual threshold
Frayser et al. Control of the retinal circulation at altitude.
Lepore et al. Supranuclear disturbances of ocular motility in Lytico‐Bodig
Das Conditioning and hypnosis.
DE19730735A1 (en) Eye oxygen-supply system
US20020116750A1 (en) Visual discomfort relief
Vogel et al. Changing therapy from timolol to betaxolol: effect on intraocular pressure in selected patients with glaucoma
FR2382240A1 (en) Ophthalmic solution diffusion equipment - delivers fine mist to cornea indirectly using cup with baffles
NIELSEN et al. Timolol: In maintenance treatment of ocular hypertension and glaucoma
Rubin et al. Effect of tertiary and quaternary atropine salts on absolute scotopic threshold changes produced by an anticholinesterase (sarin)
HAPNES Soft contact lenses worn at a simulated altitude of 18 000 feet
Zimmerman et al. Therapeutic index of epinephrine and dipivefrin with nasolacrimal occlusion

Legal Events

Date Code Title Description
8130 Withdrawal